Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Does Imlygic Make The Case For FDA Oncology Center Of Excellence?

Executive Summary

Products like Amgen's viral therapy for melanoma could benefit under proposals to replace FDA's modality-based organization with disease-specific centers. FDA's biologics center proved itself capable of reviewing the oncologic, but the drugs center already had extensive recent experience with the fast-changing melanoma market.


Related Content

Patient Voices Swayed FDA's Imlygic Review Team
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Melanoma Approvals Break New Ground In Immunotherapy
Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review


Related Companies